Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients

Abdulwahab, J., Al-Tourah, A.J., Savage, K.J., Gill, K.K., Klasa, R.J., Sehn, L., Shenkler, T.N., Gascoyne, R.D. & Connors, J.M. (2007) Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood (ASH Annual Meeting Abstracts), 110, 790. Eide, M.B., Lauritzen, G.F., Kvalheim, G., Kolstad, A., Fagerli, U.M., Maisenholder, M., Ostenstad, B., Fluge, O., Delabie, J., Aarset, H., Liestol, K. & Holte, H. (2011) High dose chemotherapy with autologous stem cell support for patients with histologically transformedB-cellnon-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology, 152, 600–610. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., de WolfPeeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361–1392. Krishnan, A., Nademanee, A., Fung, H.C., Raubitschek, A.A., Molina, A., Yamauchi, D., Rodriguez, R., Spielberger, R.T., Falk, P., Palmer, J.M. & Forman, S.J. (2008) Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 26, 90–95. Robertson, L.E., Redman, J.R., Buter, J.J., Osborne, B.M., Velasquez, W.S., McLaughlin, P., Swan, F., Rodriguez, M.A., Hagemeister, F.B. & Fuller, L.M. (1991) Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical pathologic entity associated with a continuous risk of relapse. Journal of Clinical Oncology, 9, 236–242. Shimoni, A., Zwas, S.T., Oksman, Y., Hardan, I., Shem-Tov, N., Yerushalmi, R., Ben-Bassat, I. & Nagler, A. (2007) Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin’s lymphoma. Experimental Hematology, 35, 534–540. Stolz, C. & Schuler, M. (2009) Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leukemia and Lymphoma, 50, 873–885. Vose, J.M., Bierman, P.J., Enke, C., Hankins, J., Bociek, G., Lynch, J.C. & Armitage, J.O. (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stemcell transplantation for relapsed non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 23, 461– 467.

[1]  F. Sellke,et al.  Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery , 2009, Circulation.

[2]  R. Kaufman,et al.  Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage , 2009, Transfusion.

[3]  S. Bélisle,et al.  Efficacy and safety of activated recombinant factor VII in cardiac surgical patients , 2009, Current opinion in anaesthesiology.

[4]  M. Schuler,et al.  Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention , 2009, Leukemia & lymphoma.

[5]  R. Lindeman,et al.  Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. , 2008, The Annals of thoracic surgery.

[6]  R. Gascoyne,et al.  Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma. , 2007 .

[7]  A. Darzi,et al.  Recombinant activated factor VII in cardiac surgery: a systematic review. , 2007, The Annals of thoracic surgery.

[8]  P. Mannucci,et al.  Drug therapy: Prevention and treatment of major blood loss , 2007 .

[9]  P. Kumar,et al.  Prevention and treatment of major blood loss. , 2007, The New England journal of medicine.

[10]  D. O'shaughnessy,et al.  Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. , 2005, British journal of anaesthesia.

[11]  S. McCluskey,et al.  Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case‐control analysis , 2005, Transfusion.

[12]  W. Muntean,et al.  Recombinant Factor VIIa Does not Induce Hypercoagulability In Vitro , 1999, Thrombosis and Haemostasis.

[13]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[14]  W. Velasquez,et al.  Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.